Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib in EGFR+ Stage I Lung Adenocarcinoma (ctDNA-MRD+)
NCT05079022Phase 2Unknown
- Sponsor
- Peking University People's Hospital
- Start
- Oct 2021
- Primary completion
- Mar 2023
- Countries
- 1
01
Overview
A Phase 2 trial of furmonertinib in lung adenocarcinoma, sponsored by Peking University People's Hospital. Status: unknown.
02
Drugs
furmonertinib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT05079022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05079022.